SCHEMBL321447

SCHEMBL321447

COC(=O)c1cc(C(=O)c2c(C)cc3ccccn23)ccc1N

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.58
L3MBTL1 Q9Y468 5/20 0.58
CYP1A2 P05177 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
POLB P06746 2/20 0.56
MAPK1 P28482 6/20 0.54
ALDH1A1 P00352 4/20 0.54
KMT2A Q03164 2/20 0.54
TDP1 Q9NUW8 2/20 0.54
MEN1 O00255 1/20 0.54
HTT P42858 3/20 0.52
GAA P10253 2/20 0.52
LMNA P02545 2/20 0.50
SMN1; SMN2 Q16637 3/20 0.47
NSD2 O96028 1/20 0.47
KDM4E B2RXH2 1/20 0.47
RAB9A P51151 1/20 0.47
ALOX12 P18054 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27758516 0.86 MAPT (0.42) MAPTL3MBTL1CYP1A2CYP2D6CYP2C9
SCHEMBL27910242 0.86 MAPT (0.42) MAPTL3MBTL1CYP1A2CYP2D6CYP2C9
SCHEMBL27737746 0.85 MAPT (0.42) MAPTL3MBTL1CYP1A2CYP2D6CYP2C9
SCHEMBL6218407 0.84 MAPT (0.60) MAPTL3MBTL1CYP1A2CYP2D6CYP2C9
SCHEMBL2981749 0.81 KDM4E (0.62) MAPTL3MBTL1CYP1A2CYP2D6CYP2C9
SCHEMBL4501200 0.81 MAPT (0.45) MAPTMAPK1ALDH1A1KMT2ATDP1
SCHEMBL321810 0.80 KMT2A (0.44) MAPTL3MBTL1CYP1A2CYP2D6CYP2C9
SCHEMBL321257 0.79 MAPT (0.43) MAPTCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL321101 0.79 KMT2A (0.43) MAPTCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL321288 0.79 MAPT (0.75) MAPTL3MBTL1CYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
EP-2590975-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 EP disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 MAPT 961/4885L3MBTL1 2551/4885CYP1A2 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.